# US 2004/0023873 A1 · Enkurin and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023873 A1
- Document ID: US20040023873A1
- Status: Published application
- Kind: A1
- Application number: 10/375,693
- Filed: 2003-02-25
- Published: 2004-02-05
- Earliest claimed: 2002-02-25
- Assignees: University of Massachusetts
- Inventors: Harvey Florman; Melissa Jungnickel; Keith Sutton
- Web page: https://patentgrep.com/patent/US20040023873A1

## CPC

- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10T 436/105831: Protein or peptide standard or control [e.g., hemoglobin, etc.]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A novel protein, enkurin, that is preferentially expressed in sperm has been discovered. Enkurin binds to TRPCs including TRPC2-S, a protein encoded by TRPC2 that is not predicted to be a calcium channel subunit. The invention includes methods of identifying compounds that affect enkurin expression or activity, and are useful, e.g., for contraception and treatment of infertility.

## Claims

### Claim 1

A method of identifying a candidate compound that modulates the expression or activity of an enkurin polypeptide, the method comprising
(a) obtaining a test sample comprising a cell that can express an enkurin polypeptide;
(b) contacting the test sample with a test compound;
(c) determining a level of expression or activity of the enkurin polypeptide in the test sample of (b);
wherein the test compound is a candidate compound for modulating enkurin expression or activity if the level of expression or activity in the test sample contacted with the test compound is different from a predetermined value.

### Claim 2 (depends on 1)

The method of claim 1, wherein enkurin activity is modulated.

### Claim 3 (depends on 1)

The method of claim 1, wherein enkurin nucleic acid expression is modulated.

### Claim 4 (depends on 1)

The method of claim 1, wherein enkurin polypeptide expression is modulated.

### Claim 5 (depends on 1)

The method of claim 1, wherein the test compound is a fusion protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein enkurin expression or activity is decreased.

### Claim 7 (depends on 1)

The method of claim 1, wherein enkurin expression or activity is increased.

### Claim 8 (depends on 1)

The method of claim 1, wherein determining the level of enkurin expression or activity comprises exposing the test sample to a compound that binds to the enkurin polypeptide and detecting levels of the compound.

### Claim 9 (depends on 8)

The method of claim 8, wherein the compound that binds to the enkurin polypeptide is an antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the enkurin polypeptide comprises SEQ ID NO:1 or 2.

### Claim 11 (depends on 1)

The method of claim 1, wherein the enkurin nucleic acid sequence comprises SEQ ID NO:12 or 20.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cell comprises an exogenous enkurin nucleic acid sequence.

### Claim 13 (depends on 1)

The method of claim 1, further comprising
(d) assaying Ca2+ influx in the presence of the test compound; and
(e) determining the amount of Ca2+ influx in the presence of the test compound compared to a reference compound such that a difference in the amount of Ca2+ influx indicates that the test compound is a candidate compound for modulating enkurin expression or activity.

### Claim 14

A method of diagnosing a disorder associated with aberrant expression of an enkurin polypeptide, the method comprising measuring enkurin polypeptide expression in a biological sample, wherein increased or decreased enkurin polypeptide expression in the biological sample compared to a control indicates a disorder associated with aberrant expression of an enkurin polypeptide.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disorder is infertility.

### Claim 16 (depends on 14)

The method of claim 14, wherein the biological sample is a sperm sample.

### Claim 17

A method of inhibiting fertility, the method comprising administering to a subject in need thereof an effective amount of a compound that decreases enkurin activity.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound comprises an antibody, an antibody fragment, or an antibody fusion that binds to an enkurin polypeptide.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antibody, antibody fragment, or antibody fusion binds to the TRPC binding domain of enkurin.

### Claim 20

A method of increasing fertility, the method comprising administering to a male subject in need thereof, an effective amount of enkurin polypeptide.

### Claim 21

A method for detecting an enkurin polypeptide in a biological sample, the method comprising:
(a) contacting the biological sample with an antibody that specifically binds an enkurin polypeptide under conditions that allow the formation of an enkurin polypeptide-antibody complex; and
(b) detecting any antibody-polypeptide complexes; wherein the presence of a complex indicates the presence of an enkurin polypeptide in the sample.

### Claim 22 (depends on 21)

The method of claim 21, wherein the biological sample is a sperm sample.

### Claim 23 (depends on 21)

The method of claim 21, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, and a recombinant antibody.

### Claim 24

A pharmaceutical composition comprising an enkurin-modulating compound.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the enkurin-modulating compound is a compound that disrupts enkurin interaction with a TRPC.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the enkurin interaction with a TRPC consists of binding to a TRPC.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the TRPC is a TRPC2 polypeptide.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein TRPC2 consists of a TRPC2-S polypeptide.

### Claim 29

An isolated nucleic acid, the nucleotide sequence of which consists of SEQ ID NO:12 or a complement thereof.

### Claim 30

An isolated nucleic acid comprising a sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 2, or of a fragment of SEQ ID NO:1 or 2, wherein the polypeptide binds to a TRPC polypeptide.

### Claim 31

A vector comprising the nucleotide sequence of SEQ ID NO:12, 20, 21, 23, 25, 27, 29, 31, 33, or 38 or a complement thereof.

### Claim 32 (depends on 29, 30)

An expression vector comprising the nucleic acid sequence of claim 29 or 30, operably linked to an expression control sequence.

### Claim 33 (depends on 31, 32)

A cultured cell comprising the vector of claim 31 or 32.

### Claim 34 (depends on 29, 30)

A cultured cell comprising the nucleic acid of claim 29 or 30, operably linked to an expression control sequence.

### Claim 35

A purified polypeptide encoded by the nucleotide sequence of SEQ ID NO:12 or 20.

### Claim 36

An purified polypeptide consisting of the sequence of SEQ ID NO:1 or 2.

### Claim 37

An antisense oligonucleotide that inhibits expression of enkurin protein encoded by SEQ ID NO:12, 20 or fragment thererof, or a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:9 or 10 or fragment thereof.

### Claim 38

An antisense oligonucleotide that inhibits expression of a protein comprising the sequence of SEQ ID NO:1 or 2 or fragment thererof or the nucleic acid encoding the amino acid sequence of SEQ ID NO:9 or 10.

### Claim 39

A purified antibody that binds specifically to the polypeptide having the amino acid sequence of SEQ ID NO:1 or 2 or a functional fragment thereof.

### Claim 40 (depends on 39)

The antibody of claim 39, wherein the antibody is a monoclonal, polyclonal, or recombinant antibody.

### Claim 41

An isolated nucleic acid, the nucleotide sequence of which consists of SEQ ID NO:21 or a complement thereof.

### Claim 42

An isolated nucleic acid comprising a sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:22, 24, 30, 26, 28, 32, 38 or of a fragment thereof.

### Claim 43 (depends on 41)

The isolated nucleic acid of claim 41, wherein the polypeptide binds to enkurin polypeptide.

### Claim 44

A vector comprising the nucleotide sequence of SEQ ID NO:21 or 33 or a complement thereof.

### Claim 45 (depends on 42, 43)

An expression vector comprising the nucleic acid sequence of claim 42 or 43, operably linked to an expression control sequence.

### Claim 46 (depends on 44, 45)

A cultured cell comprising the vector of claim 44 or 45.

### Claim 47 (depends on 42, 43)

A cultured cell comprising the nucleic acid of claim 42 or 43, operably linked to an expression control sequence.

### Claim 48

A purified polypeptide encoded by the nucleotide sequence of SEQ ID NO:21 or 33.

### Claim 49

An purified polypeptide consisting of the sequence of SEQ ID NO:22, 24, 26, 28, 30, or 32.

### Claim 50

An antisense oligonucleotide that inhibits expression of 5′ extended TRPC2 protein encoded by SEQ ID NO:29, 30, 38, or 39, or fragment thereof.

### Claim 51

An antisense oligonucleotide that inhibits expression of a protein comprising the sequence of SEQ ID NO:22, 24, 26, 28, 30, or 32.

### Claim 52

A purified antibody that binds specifically to the polypeptide having the amino acid sequence of SEQ ID NO: 22, 24, 26, 28, 30, or 32 or a functional fragment thereof.

### Claim 53 (depends on 52)

The antibody of claim 52, wherein the antibody is a monoclonal, polyclonal, or recombinant antibody.

### Claim 54

A method of modulating an acrosome reaction (AR) of a sperm, the method comprising contacting the sperm with a compound that modulates the expression or activity of an enkurin polypeptide or a TRPC2-S polypeptide in an amount sufficient to inhibit or to activate the AR.

### Claim 55

A method of promoting fertilization by stimulating the acrosome reaction, the method comprising the step of contacting a sperm with an effective amount of a compound that modulates the expression or activity or an enkurin or of a TRPC2-S.

### Claim 56 (depends on 55)

The method of claim 55 as applied to in vitro fertilization or artificial insemination.

### Claim 57 (depends on 55)

The method of claim 55 in which the compound is administered vaginally to a female subject.

### Claim 58 (depends on 55)

The method of claim 55 in which compound is administered systemically or locally to a male subject for promoting fertilization.

### Claim 59

A method of inhibiting the acrosome reaction, the method comprising the step of contacting a sperm with an effective amount of a compound that modulates the expression or activity of an enkurin, 5′ extended TRPC2 or splice variant thereof, or TRPC2-S or splice variant thereof.

### Claim 60 (depends on 59)

The method of claim 59, wherein the compound comprises the sequence of SEQ ID NO:38.

### Claim 61 (depends on 59)

The method of claim 59 in which the compound is administered vaginally to a female subject.

### Claim 62 (depends on 59)

The method of claim 59 in which the compound is administered systemically or locally to a male subject for blocking fertilization.

### Claim 63

A method of identifying a candidate compound that modulates the expression or activity of a 5′ extended TRPC2 polypeptide or splice variant thereof, the method comprising
(a) obtaining a test sample comprising a cell that can express a 5′ extended TRPC2 polypeptide or a polypeptide of a splice variant thereof;
(b) contacting the test sample with a test compound;
(c) determining a level of expression or activity of the 5′ extended TRPC2 polypeptide or the polypeptide of a splice variant thereof in the test sample of (b); wherein the test compound is a candidate compound for modulating 5′ extended TRPC2 polypeptide or the polypeptide of a splice variant thereof, expression or activity if the level of expression or activity in the test sample contacted with the test compound is different from a predetermined value.

### Claim 64 (depends on 63)

The method of claim 63, wherein 5′ extended TRPC2 polypeptide or splice variant thereof polypeptide activity is modulated.

### Claim 65 (depends on 63)

The method of claim 63, wherein 5′ extended TRPC2 nucleic acid or splice variant thereof, expression is modulated.

### Claim 66 (depends on 63)

The method of claim 63, wherein 5′ extended TRPC2 or 5′ extended TRPC2 splice variant expression is modulated.

### Claim 67 (depends on 63)

The method of claim 63, wherein the test compound is a fusion protein.

### Claim 68 (depends on 63)

The method of claim 63, wherein 5′ extended TRPC2 or 5′ extended TRPC2 splice variant expression or activity is decreased.

### Claim 69 (depends on 63)

The method of claim 63, wherein 5′ extended TRPC2 or 5′ extended TRPC2 splice variant expression or activity is increased.

### Claim 70 (depends on 63)

The method of claim 63, wherein determining the level of 5′ extended TRPC2 or 5′ extended TRPC2 splice variant expression or activity comprises exposing the test sample to a compound that binds to the 5′ extended TRPC2 polypeptide or 5′ extended TRPC2 splice variant polypeptide and detecting levels of the compound.

### Claim 71 (depends on 70)

The method of claim 70, wherein the compound that binds to the 5′ extended TRPC2 polypeptide or 5′ extended TRPC2 splice variant polypeptide is an antibody.

### Claim 72 (depends on 63)

The method of claim 63, wherein the 5′ extended TRPC2 polypeptide or 5′ extended TRPC2 splice variant polypeptide comprises SEQ ID NO:22, 24, 26, 28, 30, 32.

### Claim 73 (depends on 63)

The method of claim 63, wherein the 5′ extended TRPC2 nucleic acid or 5′ extended TRPC2 splice variant nucleic acid sequence comprises SEQ ID NO:29 or 31.

### Claim 74 (depends on 63)

The method of claim 63, wherein the cell comprises an exogenous 5′ extended TRPC2 nucleic acid sequence or 5′ extended TRPC2 splice variant nucleic acid sequence.

### Claim 75 (depends on 63)

The method of claim 63, further comprising
(d) assaying Ca2+ influx in the presence of the test-compound; and
(e) determining the amount of Ca2+ influx in the presence of the test compound compared to a reference compound such that a difference in the amount of Ca2+ influx indicates that the test compound is a candidate compound for modulating 5′ extended TRPC2 or 5′ extended TRPC2 splice variant expression or activity.
